ALTO news

Alto Neuroscience is offering its CFO a $6M retention package following his promotion to President and CFO, divided into two installments paid over two years. This grant is intended to be 409A compliant.

Alto granted authority for an at-the-market offering of up to $50 million shares. This authorization influences liquidity and cap table management.

Alto Ingredients reported a Q2 2026 net income of $11.4 million marked by a significant increase in net income and adjusted EBITDA compared to the prior year, aided by earnings from 45Z tax credits.

Alto Neuroscience Inc. confirmed an agreement with BofA Securities to sell 3.77 million common shares. This filing outlines the terms for the registered direct offering of new equity.

Alto Ingredients filed a document outlining its 2026 Omnibus Incentive Plan to replace the predecessor plan. This provides stock-based awards to key personnel, signaling the company's strategy to attract and retain talent.